The α-glucosidase inhibitor acarbose improves sensitivity to insulin and decreases postprandial hyperglycaemia, thereby releasing the stress on the β cells
Acarbose extends longevity and modulates FGF21 and insulin-like growth factor-I (IGF-I) in mice
It has now been demonstrated that diet and exercise, metformin, acarbose, and troglitazone can prevent or at least delay the development of diabetes in subjects with impaired glucose tolerance (IGT)
Acarbose is sometimes used in combination with insulin or other diabetes medications you take by mouth
The aim of the present study is to assess the therapeutic efficacy of Acarbose in obese type 2 diabetic patients on both insulin resistance and insulin secretion
Acarbose use also led to a statistically significant reduction in regular insulin use
Received wisdom indicated that acarbose could improve mean haemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) by reducing plasma glucose concentration [1, 2]
lower serum glucose to physiologic range
Weight and diabetes, especially type 2 diabetes, are closely related
The primary end point of this study was to evaluate the effects of 7-month treatment with acarbose on insulin resistance parameters in type 2 diabetic patients before and after an OFL; we also evaluated glycemic and lipid proï¬ le variations before and after an OFL as secondary end points